{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-224139","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2024-09-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.017143+00:00","generated_at":"2026-05-31T01:59:20.260499+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BioMarin reaffirms long-term guidance: ~$4B revenue by 2027, 40% margin from 2026","bullets":["Reaffirms ~$4B total revenues in 2027.","Non-GAAP operating margin of 40% starting in 2026, growing to low- to mid-40% range.","Targets >$1.25B operating cash flow per year starting in 2027.","Mid-teen CAGR for total revenues through 2034.","Potential treatments for skeletal conditions represent >$5B revenue opportunity."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-224139","json":"https://secwatch.observer/filing/0001193125-24-224139.json","markdown":"https://secwatch.observer/filing/0001193125-24-224139.md","text":"https://secwatch.observer/filing/0001193125-24-224139.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000119312524224139/0001193125-24-224139-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000119312524224139/d887671d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T01:59:20.260499+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}